Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 5/20 | 0.43 |
| ▸ | CDK9 | P50750 | 4/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.43 |
| ▸ | CDK1 | P06493 | 2/20 | 0.43 |
| ▸ | CDK4 | P11802 | 2/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.43 |
| ▸ | CCND1 | P24385 | 2/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.43 |
| ▸ | CDK7 | P50613 | 2/20 | 0.43 |
| ▸ | CCNH | P51946 | 2/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.43 |
| ▸ | CDK3 | Q00526 | 2/20 | 0.43 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.42 |
| ▸ | CSNK2B | P67870 | 5/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 4/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21877653 | 0.89 | CDK9 (0.48) | CDK2CDK9CCNT1CDK1CDK4 | |
| SCHEMBL26871370 | 0.83 | CDK9 (0.52) | CDK2CDK9CCNT1CDK1CDK4 | |
| SCHEMBL21877709 | 0.83 | CDK9 (0.52) | CDK2CDK9CCNT1CDK1CDK4 | |
| SCHEMBL26874278 | 0.82 | CDK9 (0.53) | CDK2CDK9CCNT1CDK1CDK4 | |
| SCHEMBL26874218 | 0.82 | CDK9 (0.53) | CDK2CDK9CCNT1CDK1CDK4 | |
| SCHEMBL21877776 | 0.82 | CDK2 (0.64) | CDK2CDK9CCNT1CDK1CDK4 | |
| SCHEMBL29558307 | 0.81 | CDK9 (0.43) | CDK2CDK9CCNT1CDK1CDK4 | |
| SCHEMBL21946102 | 0.80 | CSNK2B (0.52) | CDK2CDK9CCNT1CDK1CDK4 | |
| SCHEMBL21946110 | 0.73 | CCNT1 (0.66) | CDK2CDK9CCNT1CDK1CDK4 | |
| SCHEMBL14413699 | 0.73 | BTK (0.50) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132506-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CDK9 ACTIVITY | Kronos Bio, Inc. (US) | 2024-04-25 | — | — | US | disclosed |
| US-11845754-B2 | Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity | Kronos Bio, Inc. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20220002305-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CDK9 ACTIVITY | Kronos Bio, Inc. (US) | 2022-01-06 | — | — | US | disclosed |
| US-20220002305-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CDK9 ACTIVITY | Kronos Bio, Inc. (US) | 2022-01-06 | — | — | US | disclosed |
| US-11155560-B2 | Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity | Kronos Bio, Inc. (US) | 2021-10-26 | — | — | US | disclosed |
| US-11155560-B2 | Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity | Kronos Bio, Inc. (US) | 2021-10-26 | — | — | US | disclosed |
| EP-3873911-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CDK9 ACTIVITY | Kronos Bio, Inc. (US) | 2021-09-08 | — | — | EP | disclosed |
| US-20200131189-A1 | Compounds, Compositions, and Methods for Modulating CDK9 Activity | IGNOTA LABS LIMITED (GB) | 2020-04-30 | — | — | US | disclosed |
| US-20200131189-A1 | Compounds, Compositions, and Methods for Modulating CDK9 Activity | IGNOTA LABS LIMITED (GB) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131189-A1 | Compounds, Compositions, and Methods for Modulating CDK9 Activity | CDK9, CDK19, CDK7 | CDK2 8/4885CDK9 1/4885CCNT1 55/4885 |
| US-20240132506-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CDK9 ACTIVITY | CDK9, CDK19, CDK7 | CDK2 8/4885CDK9 1/4885CCNT1 55/4885 |
| US-11845754-B2 | Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity | CDK9, CDK19, CDK7 | CDK2 9/4885CDK9 1/4885CCNT1 40/4885 |
| US-20220002305-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CDK9 ACTIVITY | CDK9, CDK19, CDK7 | CDK2 8/4885CDK9 1/4885CCNT1 55/4885 |
| US-11155560-B2 | Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity | CDK9, CDK19, CDK7 | CDK2 9/4885CDK9 1/4885CCNT1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.